Table 7.
Acute adverse events recorded during concurrent high-dose intensity-modulated radiation therapy and docetaxel-based chemotherapy: genitourinary symptoms
| Grade |
Frequency/urgency |
Dysuria |
Incontinence |
Retention |
Hematuria |
Highest |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| B | A | A* | B | A | A* | B | A | A* | B | A | A* | B | A | A* | A | A* | ||
| Cohort 1 |
1 |
3 |
6 |
3 |
1 |
2 |
1 |
3 |
4 |
1 |
0 |
2 |
2 |
0 |
1 |
1 |
9 |
5 |
| 2 |
1 |
3 |
2 |
0 |
0 |
0 |
3 |
4 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
7 |
3 |
|
| 3 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
| Cohort 2 |
1 |
3 |
7 |
4 |
2 |
2 |
1 |
0 |
2 |
2 |
3 |
5 |
2 |
0 |
2 |
2 |
8 |
6 |
| 2 |
3 |
5 |
2 |
0 |
1 |
1 |
0 |
1 |
1 |
2 |
3 |
1 |
0 |
1 |
1 |
8 |
4 |
|
| 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | |
B = baseline (before concurrent intensity-modulated radiation therapy and docetaxel-based chemotherapy); A = all acute adverse events; A* = acute adverse events of higher grade than baseline.